Articles Meeting the needs of cancer patients and healthcare provider... Complex and evolving cancer treatment pathways require comprehensive and tailored support programmes.
News Kadcyla finally gets OK after price cut and NICE concessions Roche’s breast cancer drug Kadcyla is set for regular NHS funding in England after the company finally agreed a deal with NICE.
News LifeArc spends Keytruda cash on R&D ignored by pharma Formerly known as MRC Technology, charity to spend Keytruda royalties on R&D considered too risky by big pharma
Views & Analysis Immunotherapies in oncology: the future of cancer treatment ... Partnerships, co-marketing and the positioning of drugs are shaping the competitive landscape in oncology.
News Scotland decision helps Opdivo in UK market access picture The last 18 months has seen groundbreaking cancer immunotherapies, led by BMS’s Opdivo and Merck Sharp & Dohme’s Keytruda hit the UK market, with both rapidly adding multiple indication
Oncology ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o... For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
